| Zacks Company Profile for Arbutus Biopharma Corporation (ABUS : NSDQ) |
|
|
| |
| • Company Description |
| Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Number of Employees: 44 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $4.31 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,116,270 shares |
| Shares Outstanding: 192.32 (millions) |
| Market Capitalization: $828.92 (millions) |
| Beta: 1.07 |
| 52 Week High: $5.10 |
| 52 Week Low: $2.71 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-1.15% |
1.68% |
| 12 Week |
16.17% |
13.66% |
| Year To Date |
31.80% |
17.41% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Lindsay Androski - President; Chief Executive Officer and Director
David C. Hastings - Chief Financial Officer
Robert Alan Beardsley - Director
Joseph Bishop - Director
Matthew Gline - Director
|
|
Peer Information
Arbutus Biopharma Corporation (CORR.)
Arbutus Biopharma Corporation (RSPI)
Arbutus Biopharma Corporation (CGXP)
Arbutus Biopharma Corporation (BGEN)
Arbutus Biopharma Corporation (GTBP)
Arbutus Biopharma Corporation (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03879J100
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/26/26
|
|
Share - Related Items
Shares Outstanding: 192.32
Most Recent Split Date: (:1)
Beta: 1.07
Market Capitalization: $828.92 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.19 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 03/26/26 |
|
|
|
| |
